Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.
Also called NCT07304817
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose other
- Phase
- Phase 2
- Enrolled
- 100 participants
- Registry
-
NCT07304817 -
2025-523743-35-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Netherlands
- Registry status
- Recruiting
Technical summary
Registry record NCT07304817. Randomized; single masking; primary purpose other. Start 2026-05-12 (actual); primary completion 2028-02 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)
- Acronym
- COMPARE-VS
- Condition
- CKD (chronic kidney disease)
- Condition
- Cardiovascular Diseases
- Condition
- Heart Failure
- Intervention (Drug)
- vicadrostat / empagliflozin combination 1
- Intervention (Drug)
- Spironolactone (drug)
- Lead sponsor
- University Medical Center Groningen
- Collaborator
- Boehringer Ingelheim
- Collaborator
- DELPHINIUM
Record details
- Record id
cardio:ct-nct07304817- Content hash
92bd3c62ada05df873d0114c77e4f984718b2997408e3b8500e8c3cbe74654ed